Review
. 2012 Dec;25(2).
doi: 10.1016/j.clon.2012.10.005.

Selecting breast cancer patients for chemotherapy: the opening of the UK OPTIMA trial

J Bartlett 1 P Canney  A Campbell  D Cameron  J Donovan  J Dunn  H Earl  A Francis  P Hall  V Harmer  H Higgins  L Hillier  C Hulme  L Hughes-Davies  A Makris  A Morgan  C McCabe  S Pinder  C Poole  D Rea  N Stallard  R Stein  
Affiliations
  • PMID: 23267818
  •     18 citations

Abstract

The mortality from breast cancer has improved steadily over the past two decades, in part because of the increased use of more effective adjuvant therapies. Thousands of women are routinely treated with intensive chemotherapy, which can be unpleasant, is expensive and is occasionally hazardous. Oncologists have long known that some of these women may not need treatment, either because they have a low risk of relapse or because they have tumour biology that makes them less sensitive to chemotherapy and more suitable for early adjuvant endocrine therapy. There is an urgent need to improve patient selection so that chemotherapy is restricted to those patients who will benefit from it. Here we review the emerging technologies that are available for improving patient selection for chemotherapy. We describe the OPTIMA trial, which has just opened to recruitment in the UK, is the latest addition to trials in this area, and is the first to focus on the relative cost-effectiveness of alternate predictive assays.

Adaptive designs for clinical trials assessing biomarker-guided treatment strategies.
J Wason, A Marshall, +2 authors, N Stallard.
Br J Cancer, 2014 Mar 29; 110(8). PMID: 24667651    Free PMC article.
Genome-based risk prediction for early stage breast cancer.
Christina Adaniel, Komal Jhaveri, Adriana Heguy, Francisco J Esteva.
Oncologist, 2014 Sep 05; 19(10). PMID: 25187476    Free PMC article.
Review.
Cost-effectiveness analysis of prognostic gene expression signature-based stratification of early breast cancer patients.
Patricia R Blank, Martin Filipits, +11 authors, Michael Gnant.
Pharmacoeconomics, 2014 Nov 19; 33(2). PMID: 25404424    Free PMC article.
Adjuvant endocrine therapy for early breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline.
O C Freedman, G G Fletcher, +4 authors, A Eisen.
Curr Oncol, 2015 Apr 08; 22(Suppl 1). PMID: 25848344    Free PMC article.
Review.
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.
Joseph A Sparano, Robert J Gray, +28 authors, George W Sledge.
N Engl J Med, 2015 Sep 29; 373(21). PMID: 26412349    Free PMC article.
Highly Cited.
Patterns of resource utilization and cost for postmenopausal women with hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer in Europe.
Guy Jerusalem, Patrick Neven, +6 authors, Fabrice Andre.
BMC Cancer, 2015 Oct 27; 15. PMID: 26498283    Free PMC article.
Clinical trial designs incorporating predictive biomarkers.
Lindsay A Renfro, Himel Mallick, +2 authors, Sumithra J Mandrekar.
Cancer Treat Rev, 2016 Feb 02; 43. PMID: 26827695    Free PMC article.
Review.
Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others.
John M S Bartlett, Jane Bayani, +18 authors, OPTIMA TMG.
J Natl Cancer Inst, 2016 May 01; 108(9). PMID: 27130929    Free PMC article.
Low Ki67/high ATM protein expression in malignant tumors predicts favorable prognosis in a retrospective study of early stage hormone receptor positive breast cancer.
Xiaolan Feng, Haocheng Li, +9 authors, Alexander Paterson.
Oncotarget, 2016 Oct 16; 7(52). PMID: 27741524    Free PMC article.
Conveying Equipoise during Recruitment for Clinical Trials: Qualitative Synthesis of Clinicians' Practices across Six Randomised Controlled Trials.
Leila Rooshenas, Daisy Elliott, +17 authors, POUT study group.
PLoS Med, 2016 Oct 19; 13(10). PMID: 27755555    Free PMC article.
Discrepancies in central review re-testing of patients with ER-positive and HER2-negative breast cancer in the OPTIMA prelim randomised clinical trial.
S E Pinder, A F Campbell, +7 authors, R C Stein.
Br J Cancer, 2017 Feb 22; 116(7). PMID: 28222072    Free PMC article.
Molecular stratification of early breast cancer identifies drug targets to drive stratified medicine.
Jane Bayani, Cindy Q Yao, +13 authors, John M S Bartlett.
NPJ Breast Cancer, 2017 Jun 27; 3. PMID: 28649643    Free PMC article.
Use of 21-gene recurrence score assay to individualize adjuvant chemotherapy recommendations in ER+/HER2- node positive breast cancer-A National Cancer Database study.
Prema P Peethambaram, Tanya L Hoskin, +3 authors, Judy C Boughey.
NPJ Breast Cancer, 2017 Oct 27; 3. PMID: 29067357    Free PMC article.
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.
Joseph A Sparano, Robert J Gray, +27 authors, George W Sledge.
N Engl J Med, 2018 Jun 05; 379(2). PMID: 29860917    Free PMC article.
Highly Cited.
In the literature: August 2018.
Valentina Gambardella, Paloma Martin-Martorell, Andrés Cervantes.
ESMO Open, 2018 Sep 21; 3(6). PMID: 30233823    Free PMC article.
The impact of Oncotype DX breast cancer assay results on clinical practice: a UK experience.
Valerie E Crolley, Husam Marashi, +12 authors, Judy King.
Breast Cancer Res Treat, 2020 Mar 15; 180(3). PMID: 32170635    Free PMC article.
Strategies to Improve Recruitment to a De-escalation Trial: A Mixed-Methods Study of the OPTIMA Prelim Trial in Early Breast Cancer.
C Conefrey, J L Donovan, +18 authors, OPTIMA Prelim Study Group.
Clin Oncol (R Coll Radiol), 2020 Feb 25; 32(6). PMID: 32089356    Free PMC article.
Propensity score analysis of the prognostic value of genomic assays for breast cancer in diverse populations using the National Cancer Data Base.
Abiola Ibraheem, Olufunmilayo I Olopade, Dezheng Huo.
Cancer, 2020 Jun 11; 126(17). PMID: 32521056    Free PMC article.